Teaching hospital Program year 2025 Source: CMS Open Payments

Ronald Reagan UCLA

CA

CCN 050262 CMS hospital 15729

Open in the dashboard

General payments

$19,144,629

2,195 payments

Research payments

$231,501,952

12,926 payments

Through program year 2025, Ronald Reagan UCLA is reported as receiving $19,144,629 in general payments and $231,501,952 in research payments from drug and medical device manufacturers.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $3,960,118 220
2025 Research $37,507,868 2,406
2024 General $2,496,770 249
2024 Research $38,867,481 1,930
2023 General $3,149,165 307
2023 Research $33,097,921 1,695
2022 General $2,606,935 290
2022 Research $31,224,002 1,517
2021 General $1,667,153 273
2021 Research $26,520,589 1,538
2020 General $2,606,138 362
2020 Research $34,073,731 2,306
2019 General $2,658,350 494
2019 Research $30,210,361 1,534

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $1,430,658 93 payments
  2. Boston Scientific Corporation $1,392,433 79 payments
  3. Illumina, Inc. $1,027,411 23 payments
  4. AstraZeneca Pharmaceuticals LP $941,613 40 payments
  5. Becton, Dickinson and Company $930,930 5 payments
  6. Amgen Inc. $839,576 17 payments
  7. KARL STORZ Endoscopy-America $815,174 622 payments
  8. Siemens Medical Solutions USA, Inc. $674,420 45 payments
  9. Abbott Laboratories $635,127 89 payments
  10. Otsuka Pharmaceutical Development & Commercialization, Inc. $571,105 5 payments
  11. Other $9,886,182 1,177 payments
What the payments were for General payments · program years 2019–2025
  1. Grant $6,796,065 446 payments
  2. Royalty or License $3,628,606 124 payments
  3. Space rental or facility fees (teaching hospital only) $2,952,991 536 payments
  4. Education $1,510,433 711 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,501,003 93 payments
  6. Long term medical supply or device loan $755,874 67 payments
  7. Gift $619,356 42 payments
  8. Consulting Fee $617,857 20 payments
  9. Charitable Contribution $566,989 21 payments
  10. Debt forgiveness $180,361 129 payments
  11. Other $15,094 6 payments
Products named General payments · program years 2019–2025
  1. Infectious Disease Devices $737,259 17 payments
  2. Tagrisso $320,938 2 payments
  3. Flexitron HDR $308,135 30 payments
  4. Infectious Disease Genetics $290,152 6 payments
  5. General - Erectile Dysfunction $267,899 4 payments
  6. NanoKnife $248,500 5 payments
  7. SET and rainbow SET $197,327 1 payment
  8. Patient SafetyNet System $197,327 1 payment
  9. Altrix $192,691 18 payments
  10. Xiaflex $159,090 6 payments
  11. Other $7,886,360 1,665 payments

A payment can name more than one product, so these amounts overlap.

2,195 general · 12,926 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

A teaching hospital's total is institutional. It is money reported as going to the hospital itself, and it is kept separate from anything reported about the individual clinicians who work there — the two are never added together.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record